Quality Control Data Review Scientist

The 3-in-1 Filter Dryer: the quality gatekeeper of peptide post-treatment. - From Cleavage, Precipitation, Washing to Drying - The Strategic Value of the 3-in-1 Filter-Dryer In the production process of peptide pharmaceuticals, SolidPhase Peptide Synthesis (SPPS) technology is already highly mature. Cleavage, precipitation, filtration, washing, and drying form an interlocking posttreatment chain. The final quality of this chain determines the difficulty of subsequent purification and the cost of the final product. Crude purity determines the difficulty of purification, and the posttreatment process determines crude purity. Peptides are highly sensitive to heat, shear, solvent residues, and crosscontamination. Traditional equipment combinations - sintered glass funnels, centrifuges, tray ovens - not only involve scattered processes and multiple material transfers, but also fail to meet the stringent requirements of peptide products for "low temperature, low shear, and full containment." That is why the 3-in-1 Filter-Dryer is becoming a "musthave configuration" for peptide API production. I. Three major Pain points in peptide posttreatment. From patent literature and industry practice, three core challenges can be clearly identified in peptide cleavage, precipitation, and drying: Pain Point 1: Multiple Material Transfers - Accumulated Risk of Contamination and Loss From the cleavage reactor to the filtration device, then to the washing vessel, then to the dryer - every transfer is an exposure, a loss, and a potential contamination. Pain Point 2: Incomplete Washing - Impurity Residue Affects Downstream Purification Crude peptide after cleavage contains TFA, ether, unreacted materials, salts, and other impurities. Traditional stepwise operations cannot achieve efficient multistage countercurrent washing. Pain Point 3: Drying Process Cannot Balance Efficiency and Quality Peptide products are heatsensitive. Lyophilization offers high quality but has long cycles and high costs; Vacuum Oven drying has long cycles and uneven results. The industry is seeking efficient lowtemperature drying solutions between lyophilization and oven drying. II. An industry signal currently unfolding. In 2026, PharmaBlock Sciences put its first peptide GMP pilot plant into operation, equipped with highspeed centrifuges and large tray dryers, achieving integrated capacity for synthesis, cleavage, purification, and lyophilization. WuXi AppTec's TIDES platform has a total SPPS reactor volume exceeding 100,000 liters, equipped with custom synthesis equipment and cleavage reactors, comprehensively reducing microbial contamination and crosscontamination risks. The global peptide API CDMO giant PolyPeptide Group is undertaking an approximately €100 million capacity expansion in Malmö, Sweden, aiming to double its SPPS capacity. Neuland is expanding its peptide facilities, with new facilities to be equipped with SPPS, preparative chromatography, lyophilizers, and other complete equipment sets. Cambrex has expanded its Waltham peptide production facility, providing fullprocess support from R&D to GMP production through SPPS, LPPS, or hybrid processes.These signals all point to the same conclusion: Peptide CDMOs are upgrading from "being able to make" to "making well." In this upgrade, the integration of filtration, washing, and drying is one of the core directions. III. The 3-in-1 Filter-Dryer: "TailorMade" for Peptide PostTreatment. Wuxi Zhanghua's 3-in-1 Filter-Dryer integrates filtration, washing, and drying into a single fully enclosed vessel, with materials "never leaving the vessel" from cleavage solution feed to dry powder discharge. "Low temperature, low shear, full containment, verifiable" - these are the four key words for peptide equipment selection, and they are also the design origin of the 3-in-1 Filter-Dryer. 1.Fully Enclosed Operation - Eliminating Contamination and Exposure Peptide products are highly sensitive to crosscontamination. The 3-in-1 Filter-Dryer operates in fully enclosed mode from feed to discharge, with a nitrogen protection system, effectively preventing material oxidation and microbial contamination, meeting GMP cleanroom requirements. 1.Deep Washing - Clearing the Path for Downstream Purification The equipment features a fully automatic spray system combined with the Stype agitator's lifting and bidirectional rotation, enabling multistage countercurrent washing. The washing liquid uniformly penetrates deep into the filter cake, effectively removing TFA, ether, salts, and other impurity residues, reducing downstream purification load. 1.Vacuum LowTemperature Drying - Protecting Peptide Activity Under vacuum, the drying temperature can be significantly reduced, avoiding peptide degradation caused by high temperatures. Meanwhile, the gentle agitation ensures uniform heat distribution, effectively preventing caking and overheating. 1.Full Process Traceability - Meeting CDMO Audit Requirements The entire process sequence is fully recorded and automatically archived by the PLC+HMI intelligent control system. For peptide CDMOs that need to submit complete quality documentation to their clients, this "electronic record" is a "passport" to enter the global supply chain. IV. Customer case: from proof of concept to GMP production. A typical challenge faced by peptide CDMO customers in production is: crude product after cleavage is filtered on a traditional sintered glass funnel, and the filter cake needs to be manually transferred to a vacuum oven for drying. This process not only has long cycles but also high material exposure risk. With the 3-in-1 Filter-Dryer, customers achieve cleavage solution filtration, cake washing, and vacuum drying within the same sealed vessel. The core values are: · Material exposure reduced from 3 times to 0 · More thorough washing, significantly improved crude purity · Drying time reduced by over 30% compared to traditional ovens · Batchtobatch consistency and traceability greatly improved V. Why choose Wuxi Zhanghua? Dimension Wuxi Zhanghua's Advantages Historical Foundation Founded in 1976, nearly 50 years of manufacturing experience in core process equipment for reaction, Crystallization, filtration, and drying Industry Position The first Chinese manufacturer to develop the 3-in-1 Filter-Dryer, and one of the drafting units of industry standard T/CSTM 00824 Special Materials Full coverage from 316L to Hastelloy, titanium, and PTFE lining, meeting the requirements of corrosive media such as TFA in peptide processes International Certifications Multiple international certifications including ASME, PED, CE, and ATEX; equipment exported worldwide Client Reputation Already serving industry leaders including Duofuduo, BYD, and Hongyuan Pharma From cleavage solution to highpurity dry powder - just one machine, one feed, one discharge. That is the core value of the 3-in-1 Filter-Dryer in peptide posttreatment. Wuxi Zhanghua Pharm & Chem Equipment Co., Ltd. Founded in 1976 · Nearly 50 years as a core manufacturer of reaction, crystallization, filtration, and drying equipment 3-in-1 Filter-Dryer (ANFD) - Applicable for peptide API cleavage posttreatment, peptide conjugate posttreatment, peptide intermediate purification, and other peptide pharmaceutical production fields Contact Zhanghua for technical proposals and case references. Tel:13961802200(WeChat same number) Email:[email protected] Table of contents. Peggy zhang. Co-Founder|20+ years Pharmaceutical Drying Equipment Manufacturer|Serving 1000+ Customers|Cooperated with Novartis, Pfizer, Bayer|Keep Looking for Novel Solutions of Reaction, Crystallization And Drying Equipment

Global Peptide Synthesis Market Outlook report 2026-2035 | set to reach USD 7 billion by 2035, driven by GLP-1 demand and manufacturing capacity expansion. The global peptide synthesis market is projected to grow from USD 4.4 billion in 2026 to USD 7 billion by 2035, registering a compound annual growth rate of 5.2% during the forecast period. Market expansion is being supported by the growing peptide therapeutics pipeline, rising demand for peptide active pharmaceutical ingredients (APIs), continued investment in manufacturing infrastructure, and increased outsourcing to specialized contract development and manufacturing organizations (CDMOs). Peptide therapeutics have gained significant commercial and clinical momentum due to their metabolic stability, biological target specificity, and binding affinity. Regulatory authorities worldwide have approved nearly 100 peptide-based therapies across major indications, including cancer, diabetes, chronic pain, HIV infection, multiple sclerosis, and osteoporosis. Demand is accelerating particularly rapidly for GLP-1 and GIP receptor agonists used in diabetes and obesity treatment. The increasing volume and complexity of these drug candidates have intensified pressure on global peptide API manufacturing capacity. Pharmaceutical and biotechnology companies are consequently outsourcing more clinical and commercial production to peptide CDMOs to reduce capital requirements, access specialized technologies, and accelerate product development timelines. Manufacturing Investment Reshapes the Peptide Synthesis Market Leading peptide manufacturers are expanding solid phase, liquid phase, and hybrid synthesis capacity while upgrading purification systems and introducing automated and AI-assisted process controls. CordenPharma, PolyPeptide, Cambrex, and other industry participants have announced major facility investments designed to address supply constraints and support next-generation peptide therapeutics. CordenPharma has committed more than EUR 900 million to capacity investment, while PolyPeptide is doubling capacity at its Malmo site and Cambrex is expanding its facility in Waltham, Massachusetts. CordenPharma's multi-year agreement with Viking Therapeutics for commercial manufacturing of the GLP-1/GIP candidate VK2735 also demonstrates the growing importance of large-scale peptide supply partnerships. Market consolidation is creating additional competitive momentum. Granules India's acquisition of Senn Chemicals in April 2025 reflects a broader trend in which diversified pharmaceutical companies are entering the peptide CDMO market through targeted transactions. Agreements involving Hybio Pharmaceutical, iCarbonX Intelligent Peptide, and Sunshine Mandi Pharmaceutical further highlight rising reliance on outsourced peptide development and commercial API production. Technology and Sustainability Support Long-Term Growth Advances in solid phase peptide synthesis, liquid phase peptide synthesis, hybrid production, microwave-assisted processing, chemo-enzymatic synthesis, and continuous flow technology are improving scalability, productivity, and cost efficiency. Hybrid synthesis is expected to record particularly strong growth because of its suitability for longer peptide sequences and structurally complex molecules. Sustainability is also becoming an important factor in CDMO selection. Traditional peptide manufacturing requires substantial solvent and resource use, increasing demand for greener production methods. EUROAPI's collaboration with StrainChem on sustainable liquid phase peptide synthesis and Innovate UK's EUR 913,659 investment in sustainable GLP-1 biomanufacturing illustrate the industry's growing focus on green chemistry. Despite favorable market conditions, manufacturers continue to face capacity shortages, supply bottlenecks, high infrastructure costs, and technical challenges associated with complex, high-volume peptides. Geographic concentration of manufacturing facilities also exposes the peptide supply chain to regional disruptions, changing trade policies, and tariff uncertainty. Key Peptide Synthesis Market Segment Insights * API type: Generic APIs are expected to retain the largest market share, supported by patent expirations for first-generation peptide drugs and demand for lower-cost alternatives to branded therapies. * Synthesis method: Chemical synthesis currently dominates due to its scalability, flexibility, cost profile, and widespread commercial adoption. * Chemical synthesis technology: Solid phase synthesis holds the leading share, while hybrid phase synthesis is projected to grow faster as development pipelines shift toward longer and more complex peptide sequences. * Scale of operation: Commercial-scale manufacturing accounts for the largest share and is expected to register strong growth, driven by high-volume GMP-grade peptide API production and long-term supply agreements. * Company size: The market includes small, mid-sized, large, and very large peptide manufacturers serving preclinical, clinical, and commercial requirements. Regional Peptide Synthesis Market Outlook Europe is projected to maintain the largest share of global peptide synthesis market revenue through 2035. The region benefits from extensive manufacturing capacity, active clinical research, established life sciences clusters, and strong academic-industry collaboration. Belgium remains a major contributor due to its biotechnology ecosystem, government support, and pharmaceutical logistics infrastructure. Switzerland is another important market, supported by Bachem's manufacturing presence and the country's integrated life sciences sector. Asia-Pacific is forecast to register the highest CAGR during the forecast period. Growth is being driven by government investment in life sciences, expanding pharmaceutical demand, skilled labor availability, and cost-competitive manufacturing. Regional companies, including WuXi STA, are strengthening Asia-Pacific's position in global peptide API production. Competitive Landscape Companies evaluated in the peptide synthesis market include Amneal Pharmaceuticals, Asymchem, Aurisco Pharma, Dr. Reddy's Laboratories, Hybio Pharmaceutical, JYMed Peptide, Neuland Labs, Sinopep-Allsino Biopharmaceutical, SK Pharmteco, and WuXi STA, a WuXi AppTec company. The competitive assessment also examines peptide API manufacturers across North America, Europe, Asia-Pacific, and other international markets. Research Coverage The market report provides peptide synthesis market sizing and forecasts by API type, synthesis method, chemical synthesis technology, operating scale, company size, and geography. It also includes company benchmarking, manufacturer profiles, facility and capacity analysis, clinical trial assessment, demand forecasting, partnership analysis, recent industry developments, and regional manufacturing capability evaluation. Additional analysis covers make-versus-buy decision frameworks, potential strategic partners, total cost of ownership over a 20-year period, and the strengths, weaknesses, opportunities, and threats affecting peptide API manufacturers and CDMOs. The research incorporates perspectives from senior industry stakeholders in Germany, the United States, Ireland, Japan, and India. The report is designed to support pharmaceutical companies, biotechnology developers, investors, peptide CDMOs, distribution partners, service providers, and other stakeholders seeking data-driven insight into market growth, manufacturing demand, capacity constraints, competitive positioning, and emerging opportunities through 2035. Report Benefits * Detailed revenue projections for the global market and key subsegments * Analysis of market drivers, barriers, trends, risks, and growth opportunities * Competitive intelligence covering established manufacturers and emerging entrants * Complementary presentation and Excel data packs * Up to 15% complimentary content customization * Research team walkthrough and a complimentary update for reports more than six months old About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Cambrex Milan celebrates its 80th anniversary with the construction of a new $30 million R&D center. Aug 11, 2026, 06:41 ET EAST RUTHERFORD, New Jersey, Aug. 11, 2026 /PRNewswire/ - Cambrex, a leading contract development and manufacturing organization (CDMO), announced today the start of construction of a new research and development (R&D) center at its Milan, Italy site. This $30 million investment will strengthen capabilities in advanced analytical development and process research and development, while modernizing several production sites, confirming Cambrex's commitment to supporting the development of the most complex small molecules in the pharmaceutical industry. The expansion of the Milan R&D center is expected to be completed in the second half of 2027. To anticipate its growth and meet the growing demand for CDMO services, Cambrex has also acquired additional land adjacent to the site, thus securing the capacity needed to grow and innovate in the years to come. Cambrex Profarmico's Milan site, which celebrates its 80th anniversary this year, can boast a long tradition of supporting the development and manufacture of pharmaceutical products for its international clientele. The Milan team recently gathered to celebrate this important milestone, reflecting on eight decades of scientific achievements and commitment to human health. Claudio Russolo, chief operating officer at Cambrex, said: "The launch of work on this new facility says a lot about the enduring legacy and expertise of our Milan team. For 80 years, this site has been a pillar of the pharmaceutical industry in Europe. With this expansion, we are investing not only in new technologies and skills, but also in the future of our employees and partners." This investment builds on the scientific expertise and industrial excellence that are the hallmark of Cambrex's reputation, while preparing the company to enter a new phase of growth. By expanding its R&D capabilities in Milan, Cambrex strengthens its ability to address the growing complexity of today's small molecule therapies. About Cambrex Cambrex is one of the world's leading contract development and manufacturing organizations (CDMO). The company offers development and manufacturing services for active substances throughout the drug lifecycle, as well as comprehensive analytical services. With more than 45 years of experience and a team of 2,000 experts serving international clients in North America and Europe, Cambrex offers a range of technologies and specialized skills in the field of drug substances, including continuous flow production, controlled substances, peptide synthesis, solid-state science, biocatalysis, material characterization, complex compound synthesis, and highly potent active pharmaceutical ingredients (HPAPI).